CJC-1295 (no DAC) vs Hexarelin
Both CJC-1295 (no DAC) and Hexarelin are used for growth-hormone and recovery. Here's how their evidence, dosing, and regulatory status actually compare.
CJC-1295 (no DAC)
Evidence BModified Growth Hormone Releasing Factor 1-29
A growth hormone releasing hormone (GHRH) analog most commonly stacked with Ipamorelin to stimulate natural GH pulsatile release without disrupting the hypothalamic axis.
View full CJC-1295 (no DAC) profile →Hexarelin
Evidence BHexarelin (HEX)
The strongest GH-releasing hexapeptide and one of the few peptides with documented direct cardiac benefits in animal models. Tachyphylaxis (diminished response over time) limits long-term use.
View full Hexarelin profile →Side-by-Side
| Attribute | CJC-1295 (no DAC) | Hexarelin |
|---|---|---|
| Evidence Grade | B | B |
| FDA Status | Not FDA-approved — Category 1 (compounding allowed) | Not FDA-approved — research compound (cardioprotective signals investigated) |
| Typical Dose | 100–300 mcg before bed (subcutaneous) | 100 mcg, 1–2 times daily (subcutaneous) |
| Clinics Indexed | 156 | 41 |
| Categories | growth-hormone, anti-aging, recovery | growth-hormone, recovery |
Key reported benefits — CJC-1295 (no DAC)
- ✓Growth hormone release
- ✓Fat loss
- ✓Improved sleep
- ✓Muscle recovery
Key reported benefits — Hexarelin
- ✓Strongest GH spike of GHRPs
- ✓Cardioprotective signals
- ✓Recovery
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.